Efficacia della Rufinamide nelle encefalopatie epilettiche secondarie a malformazioni cerebrali complesse

Translated title of the contribution: Efficacy of Rufinamide in epileptic encephalopathies secondary to complex brain malformations

F. Madeddu, R. Moavero, D. Battaglia, S. Matricardi, G. Coppola, M. Balestri, A. Capuano, P. Curatolo, A. Verrotti, F. Vigevano, D. Pruna, R. Cusmai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim of this study was the evaluation of efficacy and tolerability of an add-on rufinamide (RFN) trial in 33 patients with epileptic encephalopathies secondary to complex brain malformations. Patients have been considered responders if seizure reduction was greater than 50%. 19/33 patients (57.6%) are responders: in particular in 9 patients seizure's reduction was greater than 50% and in 10 was greater than 75%. The mean follow-up was 15.1 months (8-36 months). All non-responder patients (42.4%) discontinued rufinamide. 21,2% of subjects presented mild and transient side effects. In one case (3,1%) RFN was discontinued because of persisting anorexia. In a another case RFN was discontinued for an increase of seizures. Our results suggest that rufinamide can be considered as a valuable adjunctive therapeutic option in epileptic encephalopathies secondary to complex brain malformations).

Original languageItalian
Pages (from-to)278-280
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number145
Publication statusPublished - Apr 2013

Fingerprint

Brain Diseases
Brain
Seizures
Anorexia
rufinamide

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Efficacia della Rufinamide nelle encefalopatie epilettiche secondarie a malformazioni cerebrali complesse. / Madeddu, F.; Moavero, R.; Battaglia, D.; Matricardi, S.; Coppola, G.; Balestri, M.; Capuano, A.; Curatolo, P.; Verrotti, A.; Vigevano, F.; Pruna, D.; Cusmai, R.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 145, 04.2013, p. 278-280.

Research output: Contribution to journalArticle

Madeddu, F, Moavero, R, Battaglia, D, Matricardi, S, Coppola, G, Balestri, M, Capuano, A, Curatolo, P, Verrotti, A, Vigevano, F, Pruna, D & Cusmai, R 2013, 'Efficacia della Rufinamide nelle encefalopatie epilettiche secondarie a malformazioni cerebrali complesse', Bollettino - Lega Italiana contro l'Epilessia, no. 145, pp. 278-280.
Madeddu, F. ; Moavero, R. ; Battaglia, D. ; Matricardi, S. ; Coppola, G. ; Balestri, M. ; Capuano, A. ; Curatolo, P. ; Verrotti, A. ; Vigevano, F. ; Pruna, D. ; Cusmai, R. / Efficacia della Rufinamide nelle encefalopatie epilettiche secondarie a malformazioni cerebrali complesse. In: Bollettino - Lega Italiana contro l'Epilessia. 2013 ; No. 145. pp. 278-280.
@article{0c83a82898af4e3ea5447fe11b66ce4e,
title = "Efficacia della Rufinamide nelle encefalopatie epilettiche secondarie a malformazioni cerebrali complesse",
abstract = "Aim of this study was the evaluation of efficacy and tolerability of an add-on rufinamide (RFN) trial in 33 patients with epileptic encephalopathies secondary to complex brain malformations. Patients have been considered responders if seizure reduction was greater than 50{\%}. 19/33 patients (57.6{\%}) are responders: in particular in 9 patients seizure's reduction was greater than 50{\%} and in 10 was greater than 75{\%}. The mean follow-up was 15.1 months (8-36 months). All non-responder patients (42.4{\%}) discontinued rufinamide. 21,2{\%} of subjects presented mild and transient side effects. In one case (3,1{\%}) RFN was discontinued because of persisting anorexia. In a another case RFN was discontinued for an increase of seizures. Our results suggest that rufinamide can be considered as a valuable adjunctive therapeutic option in epileptic encephalopathies secondary to complex brain malformations).",
keywords = "Complex brain malformations, Epileptic encephalopathies, Long-term follw-up, Rufinamide",
author = "F. Madeddu and R. Moavero and D. Battaglia and S. Matricardi and G. Coppola and M. Balestri and A. Capuano and P. Curatolo and A. Verrotti and F. Vigevano and D. Pruna and R. Cusmai",
year = "2013",
month = "4",
language = "Italian",
pages = "278--280",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "145",

}

TY - JOUR

T1 - Efficacia della Rufinamide nelle encefalopatie epilettiche secondarie a malformazioni cerebrali complesse

AU - Madeddu, F.

AU - Moavero, R.

AU - Battaglia, D.

AU - Matricardi, S.

AU - Coppola, G.

AU - Balestri, M.

AU - Capuano, A.

AU - Curatolo, P.

AU - Verrotti, A.

AU - Vigevano, F.

AU - Pruna, D.

AU - Cusmai, R.

PY - 2013/4

Y1 - 2013/4

N2 - Aim of this study was the evaluation of efficacy and tolerability of an add-on rufinamide (RFN) trial in 33 patients with epileptic encephalopathies secondary to complex brain malformations. Patients have been considered responders if seizure reduction was greater than 50%. 19/33 patients (57.6%) are responders: in particular in 9 patients seizure's reduction was greater than 50% and in 10 was greater than 75%. The mean follow-up was 15.1 months (8-36 months). All non-responder patients (42.4%) discontinued rufinamide. 21,2% of subjects presented mild and transient side effects. In one case (3,1%) RFN was discontinued because of persisting anorexia. In a another case RFN was discontinued for an increase of seizures. Our results suggest that rufinamide can be considered as a valuable adjunctive therapeutic option in epileptic encephalopathies secondary to complex brain malformations).

AB - Aim of this study was the evaluation of efficacy and tolerability of an add-on rufinamide (RFN) trial in 33 patients with epileptic encephalopathies secondary to complex brain malformations. Patients have been considered responders if seizure reduction was greater than 50%. 19/33 patients (57.6%) are responders: in particular in 9 patients seizure's reduction was greater than 50% and in 10 was greater than 75%. The mean follow-up was 15.1 months (8-36 months). All non-responder patients (42.4%) discontinued rufinamide. 21,2% of subjects presented mild and transient side effects. In one case (3,1%) RFN was discontinued because of persisting anorexia. In a another case RFN was discontinued for an increase of seizures. Our results suggest that rufinamide can be considered as a valuable adjunctive therapeutic option in epileptic encephalopathies secondary to complex brain malformations).

KW - Complex brain malformations

KW - Epileptic encephalopathies

KW - Long-term follw-up

KW - Rufinamide

UR - http://www.scopus.com/inward/record.url?scp=84887275043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887275043&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:84887275043

SP - 278

EP - 280

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 145

ER -